Andexxa will go nationwide with FDA nod on Portola's commercial production of the bleeding antidote

Portola will finally see the commercial release of its universal bleeding reversal agent Andexxa, a milestone not only for the biotech but also for Pfizer and Bristol-Myers Squibb, as well as Bayer and Johnson & Johnson, whose blood thinners rely on it as a bleeding antidote.